SCHEMBL374807

SCHEMBL374807

Oc1c(-c2ccc3ccccc3c2O)ccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN22 Q9Y2R2 1/20 0.65
HSD17B10 Q99714 2/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP2A6 P11509 1/20 0.55
TSHR P16473 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
LDHA P00338 1/20 0.54
CYP1A2 P05177 2/20 0.50
HPRT1 P00492 1/20 0.50
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
HIF1A Q16665 1/20 0.48
POLB P06746 1/20 0.48
USP2 O75604 1/20 0.46
PAK1 Q13153 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29401627 1.00 PTPN22 (0.65) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
SCHEMBL1840828 0.97 PTPN22 (0.62) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
SCHEMBL5155985 0.97 PTPN22 (0.62) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
SCHEMBL9060860 0.97 PTPN22 (0.62) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
SCHEMBL6634384 0.93 PTPN22 (0.58) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
SCHEMBL8735056 0.93 PTPN22 (0.58) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
SCHEMBL7829341 0.91 PTPN22 (0.56) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
Sulfur Dioxide SCHEMBL20526198 0.91 PTPN22 (0.56) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
SCHEMBL9510182 0.91 PTPN22 (0.56) PTPN22HSD17B10ALDH1A1CYP2A6TSHR
SCHEMBL4443508 0.91 PTPN22 (0.56) PTPN22HSD17B10ALDH1A1CYP2A6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12163968-B2 Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers BIO-RAD LABORATORIES, INC. (US) 2024-12-10 US claimed
CN-118268043-A All-organic heterojunction photocatalyst and preparation method thereof 淮北师范大学 2024-07-02 CN claimed
CN-116396269-A Method for obtaining (R) -alpha-lipoic acid through inclusion resolution 天驰药业有限公司 2023-07-07 CN claimed
CN-109336887-B Benzimidazole chiral heterocyclic compound and preparation method and application thereof 中山大学 2021-12-17 CN claimed
EP-3527639-B1 A METHOD FOR BONDING A THERMOPLASTIC MATERIAL BY MICROWAVE-IRRADIATION PROIONIC GMBH (AT) 2021-09-08 EP claimed
US-11084954-B2 Method for curing an adhesive using microwave irradiation PROIONIC GMBH (AT) 2021-08-10 US claimed
CN-112427015-A Microporous carbon and preparation method thereof 杭州肄康新材料有限公司 2021-03-02 CN claimed
US-10900941-B2 Determining stereoisomeric excess, concentration and absolute configuration GEORGETOWN UNIVERSITY (US) 2021-01-26 US claimed
WO-2020054356-A1 EPOXY RESIN CURING ACCELERATOR AND EPOXY RESIN COMPOSITION サンアプロ株式会社 2020-03-19 WO claimed
EP-3527639-A1 A METHOD FOR BONDING A THERMOPLASTIC MATERIAL BY MICROWAVE-IRRADIATION proionic GmbH (AT) 2019-08-21 EP claimed
EP-1697387-A1 METHOD FOR PRODUCING TRIVALENT ORGANOPHOSPHORUS COMPOUNDS Oxeno Olefinchemie GmbH (DE) 2006-09-06 EP claimed
WO-2005063776-A1 METHOD FOR PRODUCING TRIVALENT ORGANOPHOSPHORUS COMPOUNDS OXENO OLEFINCHEMIE GMBH (DE) 2005-07-14 WO claimed
US-6835838-B2 Condensation of silicon compounds with aldehydes in the presence of titanium catalysts in solvents, then reducing and hydolyzing to form drugs used for prophylaxis of atherosclerosis or as enzyme inhibitors NOVARTIS AG (CH) 2004-12-28 US claimed
US-20040249154-A1 Process for the manufacture of organic compounds CHEN GUANG-PEI (US) 2004-12-09 US claimed
EP-1472227-A2 PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS Novartis AG (CH) 2004-11-03 EP claimed
US-20030208072-A1 Process for the manufacture of organic compounds NOVARTIS AG (CH) 2003-11-06 US claimed
WO-2003064382-A2 PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS NOVARTIS AG (CH) 2003-08-07 WO claimed
EP-0633501-A2 Photosensitive material and image forming method CANON KABUSHIKI KAISHA (JP) 1995-01-11 EP claimed
US-4804415-A COUPLING AROMATIC DIAZONIUM COMPOUND WITH 3-HYDROXY-2-NAPHTHOIC AICD AND BINAPHTHOL KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) 1989-02-14 US claimed
US-3997346-A Method for stabilizing the image of a thermally developable photosensitive material FUJI PHOTO FILM CO., LTD. (JA) 1976-12-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249154-A1 Process for the manufacture of organic compounds HSD11B1, HSD3B1, HSD11B2 PTPN22 4238/4885HSD17B10 30/4885ALDH1A1 223/4885
US-20030208072-A1 Process for the manufacture of organic compounds HSD11B1, HSD3B1, HSD11B2 PTPN22 4238/4885HSD17B10 30/4885ALDH1A1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.